Login to Your Account

Repligen Raises $12.5 Privately To Advance Secretin Program

By Brady Huggett

Monday, May 5, 2003
Repligen Corp. raised $12.5 million through a private placement and will use the funds in part for its Phase III product, secretin, also called RG1068. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription